Should Methotrexate plus Calcineurin Inhibitors Be Considered Standard of Care for Prophylaxis of acute Graft-versus-Host Disease? Rainer Storb, Joseph H. Antin, Corey Cutler Biology of Blood and Marrow Transplantation Volume 16, Issue 1, Pages S18-S27 (January 2010) DOI: 10.1016/j.bbmt.2009.10.016 Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Survival and cGVHD in patients with aplastic anemia (2-63 years old) given HLA matched-related grafts and receiving MTX/CsA after conditioning with cyclophosphamide and antithymocyte globulin (Cy/ATG) [87]. Similar results have been reported in children by Locatelli et al. [88]. Biology of Blood and Marrow Transplantation 2010 16, S18-S27DOI: (10.1016/j.bbmt.2009.10.016) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 2 Survival of patients with chronic myelogenous leukemia in chronic phase (CML-CP) given HLA-matched unrelated HCT and receiving MTX/CsA after conditioning with cyclophosphamide and total body irradiation (Cy/TBI) [89]. This represents a subgroup of patients who received prophylaxis with fluconazole and ganciclovir. Biology of Blood and Marrow Transplantation 2010 16, S18-S27DOI: (10.1016/j.bbmt.2009.10.016) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions